The Nordics-led by Sweden, Denmark, and Norway-have carved out a highly specialised niche in the ADC market, focusing on Radio-immunotherapy, Affibody® molecules, and next-generation site-specific conjugation. The region is defined by its massive pharmaceutical heritage (e.g., Novo Nordisk, AstraZeneca) and a world-leading "triple helix" model where government-funded clinical centers, academia, and private biotechs are seamlessly integrated.